Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein.

Barkovits K, Kruse N, Linden A, Tönges L, Pfeiffer K, Mollenhauer B, Marcus K.

Cells. 2020 Feb 5;9(2). pii: E370. doi: 10.3390/cells9020370.

2.

Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection.

Kruse N, Mollenhauer B.

Methods Mol Biol. 2019;1948:59-68. doi: 10.1007/978-1-4939-9124-2_6.

PMID:
30771170
3.

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease.

Kruse N, Heslegrave A, Gupta V, Foiani M, Villar-Piqué A, Schmitz M, Lehmann S, Teunissen C, Blennow K, Zetterberg H, Mollenhauer B, Zerr I, Llorens F.

Alzheimers Dement (Amst). 2018 Jul 7;10:461-470. doi: 10.1016/j.dadm.2018.06.005. eCollection 2018.

4.

Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.

Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty JM, Smith CL, Stoops E, Vanderstichele H, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H.

J Neurochem. 2019 Apr;149(1):126-138. doi: 10.1111/jnc.14569. Epub 2018 Nov 13.

5.

Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid.

Kruse N, El-Agnaf OM, Mollenhauer B.

Bioanalysis. 2017 Apr;9(8):621-630. doi: 10.4155/bio-2017-0005. Epub 2017 May 15.

PMID:
28504552
6.

Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease.

Llorens F, Kruse N, Karch A, Schmitz M, Zafar S, Gotzmann N, Sun T, Köchy S, Knipper T, Cramm M, Golanska E, Sikorska B, Liberski PP, Sánchez-Valle R, Fischer A, Mollenhauer B, Zerr I.

Mol Neurobiol. 2018 Mar;55(3):2249-2257. doi: 10.1007/s12035-017-0479-5. Epub 2017 Mar 21.

7.

Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt-Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress.

Tahir W, Zafar S, Llorens F, Arora AS, Thüne K, Schmitz M, Gotzmann N, Kruse N, Mollenhauer B, Torres JM, Andréoletti O, Ferrer I, Zerr I.

Mol Neurobiol. 2018 Jan;55(1):517-537. doi: 10.1007/s12035-016-0294-4. Epub 2016 Dec 14.

8.

Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases.

Llorens F, Kruse N, Schmitz M, Gotzmann N, Golanska E, Thüne K, Zejneli O, Kanata E, Knipper T, Cramm M, Lange P, Zafar S, Sikorska B, Liberski PP, Mitrova E, Varges D, Schmidt C, Sklaviadis T, Mollenhauer B, Zerr I.

Alzheimers Dement. 2017 Jun;13(6):710-719. doi: 10.1016/j.jalz.2016.09.013. Epub 2016 Nov 18.

PMID:
27870938
9.

Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration.

Miller AM, Rutkowska A, Bahl JM, Herukka SK, Koel-Simmelink MJ, Kruse N, Mollenhauer B, Siloaho M, Skinningsrud A, Zetterberg H, Teunissen CE, Lawlor BA.

Bioanalysis. 2016 Nov;8(21):2243-2254. Epub 2016 Sep 29.

PMID:
27684648
10.

Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.

Llorens F, Schmitz M, Varges D, Kruse N, Gotzmann N, Gmitterová K, Mollenhauer B, Zerr I.

J Neurol. 2016 Nov;263(11):2271-2277. Epub 2016 Aug 20.

PMID:
27544498
11.

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.

Kruse N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, Vanderstichele H, El-Agnaf OM, Mollenhauer B.

PLoS One. 2016 Apr 26;11(4):e0153564. doi: 10.1371/journal.pone.0153564. eCollection 2016.

12.

Quantified CSF antibody reactivity against myelin in multiple sclerosis.

Sun X, Bakhti M, Fitzner D, Schnaars M, Kruse N, Coskun Ü, Kremser C, Willecke K, Kappos L, Kuhle J, Simons M.

Ann Clin Transl Neurol. 2015 Nov 9;2(12):1116-23. doi: 10.1002/acn3.264. eCollection 2015 Dec.

13.

Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.

Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A.

Brain. 2016 Feb;139(Pt 2):481-94. doi: 10.1093/brain/awv346. Epub 2015 Dec 8.

14.

A Practical Guide to Immunoassay Method Validation.

Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S, Kruse N, Kuiperij HB, Kulic L, Lewczuk P, Mollenhauer B, Mroczko B, Parnetti L, Vanmechelen E, Verbeek MM, Winblad B, Zetterberg H, Koel-Simmelink M, Teunissen CE.

Front Neurol. 2015 Aug 19;6:179. doi: 10.3389/fneur.2015.00179. eCollection 2015.

15.

Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid.

Kruse N, Mollenhauer B.

J Immunol Methods. 2015 Nov;426:70-5. doi: 10.1016/j.jim.2015.08.003. Epub 2015 Aug 10.

PMID:
26271436
16.

Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.

Llorens F, Kruse N, Schmitz M, Shafiq M, da Cunha JE, Gotzman N, Zafar S, Thune K, de Oliveira JR, Mollenhauer B, Zerr I.

J Neurol. 2015 Oct;262(10):2305-11. doi: 10.1007/s00415-015-7837-x. Epub 2015 Jul 11.

PMID:
26162713
17.

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study.

Kruse N, Persson S, Alcolea D, Bahl JM, Baldeiras I, Capello E, Chiasserini D, Bocchio Chiavetto L, Emersic A, Engelborghs S, Eren E, Fladby T, Frisoni G, García-Ayllón MS, Genc S, Gkatzima O, Heegaard NH, Janeiro AM, Kováčech B, Kuiperij HB, Leitão MJ, Lleó A, Martins M, Matos M, Mollergard HM, Nobili F, Öhrfelt A, Parnetti L, de Oliveira CR, Rot U, Sáez-Valero J, Struyfs H, Tanassi JT, Taylor P, Tsolaki M, Vanmechelen E, Verbeek MM, Zilka N, Blennow K, Zetterberg H, Mollenhauer B.

Neurobiol Aging. 2015 Sep;36(9):2587-96. doi: 10.1016/j.neurobiolaging.2015.05.003. Epub 2015 May 15.

PMID:
26093515
18.

Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation.

Kunadt M, Eckermann K, Stuendl A, Gong J, Russo B, Strauss K, Rai S, Kügler S, Falomir Lockhart L, Schwalbe M, Krumova P, Oliveira LM, Bähr M, Möbius W, Levin J, Giese A, Kruse N, Mollenhauer B, Geiss-Friedlander R, Ludolph AC, Freischmidt A, Feiler MS, Danzer KM, Zweckstetter M, Jovin TM, Simons M, Weishaupt JH, Schneider A.

Acta Neuropathol. 2015 May;129(5):695-713. doi: 10.1007/s00401-015-1408-1. Epub 2015 Mar 17.

19.

Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model.

Häusler D, Nessler S, Kruse N, Brück W, Metz I.

Neuropathol Appl Neurobiol. 2015 Oct;41(6):814-31. doi: 10.1111/nan.12220. Epub 2015 May 2.

PMID:
25641089
20.

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis.

Grey Née Cotte S, Salmen Née Stroet A, von Ahsen N, Starck M, Winkelmann A, Zettl UK, Comabella M, Montalban X, Zipp F, Fleischer V, Kruse N, Gold R, Chan A.

J Neuroimmunol. 2015 Jan 15;278:277-9. doi: 10.1016/j.jneuroim.2014.11.017. Epub 2014 Nov 20.

PMID:
25468777

Supplemental Content

Loading ...
Support Center